Neuronox for Glabellar Lines: What the Randomized Phase III Trial Found

An evidence-based overview of botulinum toxin type A, including its mechanism of action, clinical uses, safety considerations and product-specific differences.

8/28/20261 min read

Clinical research documents and tablet on a clean white desk
Clinical research documents and tablet on a clean white desk

Botulinum toxin type A (BoNT-A) is a neurotoxin used in selected therapeutic and aesthetic settings. Its clinical effect is produced by reducing acetylcholine release at the neuromuscular junction, which temporarily decreases activity in targeted muscles. BoNT-A products are not simply interchangeable labels for one identical medicine: formulations, product-specific units, approved indications and supporting clinical evidence must be interpreted for each product.

Design of Pivotal Phase III Trials

Multi-center double-blind randomized trials evaluated adult subjects presenting with moderate-to-severe glabellar lines at maximum frown. Participants were assigned to receive equal unit doses of either Neuronox or a comparator botulinum toxin type A formulation. Standardized photographic documentation and validated investigator ratings served as the primary endpoints at regular four-week intervals post-injection.

Efficacy Outcomes and Response Rates

The trial results demonstrated statistical non-inferiority to the reference control, with over eighty-five percent of subjects achieving significant improvement at week four. Response rates remained high through week eight before gradually diminishing toward baseline by week sixteen. Patient self-assessment questionnaires aligned closely with investigator ratings, confirming high aesthetic satisfaction rates.

Adverse Events and Tolerability Profile

Safety monitoring revealed a favorable adverse event profile, with mild localized discomfort at the injection site being the most frequently reported event. Complications such as eyebrow ptosis occurred at minimal rates comparable across study arms. Overall, the clinical evidence confirms that Neuronox provides predictable correction of glabellar lines with established safety parameters.

• COMPLETE SITE INDEX

BotoxWiki Reference Sitemap

Access all clinical evidence methodologies, facial anatomy maps, brand comparison data, and editorial standards currently published across the BotoxWiki platform.

Clinical & Anatomy

Evidence & Review

Editorial & Trust

Reference Standard

BotoxWiki provides evidence-based content, medical review, and a neutral editorial approach to botulinum toxin formulations and anatomical guidance.

© BotoxWiki Clinical Reference Directory.

All anatomical models, literature reviews, and evidence summaries are strictly peer-reviewed and non-commercial.